STERIS plc $STE Shares Sold by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc cut its position in shares of STERIS plc (NYSE:STE) by 11.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,777 shares of the medical equipment provider’s stock after selling 4,014 shares during the period. Marks Group Wealth Management Inc’s holdings in STERIS were worth $7,803,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Nordea Investment Management AB increased its holdings in shares of STERIS by 259.0% during the 4th quarter. Nordea Investment Management AB now owns 51,602 shares of the medical equipment provider’s stock worth $13,165,000 after buying an additional 37,228 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of STERIS by 9.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,039,351 shares of the medical equipment provider’s stock worth $257,157,000 after buying an additional 89,250 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of STERIS by 5.3% during the 3rd quarter. Legal & General Group Plc now owns 693,116 shares of the medical equipment provider’s stock worth $171,505,000 after buying an additional 34,981 shares during the last quarter. Elo Mutual Pension Insurance Co acquired a new stake in shares of STERIS during the 3rd quarter worth approximately $2,480,000. Finally, Groupama Asset Managment acquired a new stake in shares of STERIS during the 3rd quarter worth approximately $1,163,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other STERIS news, CEO Daniel A. Carestio sold 1,374 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $212.00, for a total transaction of $291,288.00. Following the sale, the chief executive officer directly owned 63,647 shares in the company, valued at $13,493,164. This represents a 2.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total transaction of $310,284.31. Following the sale, the director owned 38,964 shares in the company, valued at approximately $8,163,347.64. This trade represents a 3.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 5,909 shares of company stock worth $1,257,083. 1.07% of the stock is owned by company insiders.

STERIS Stock Performance

NYSE:STE opened at $210.19 on Tuesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.54 and a current ratio of 2.09. The stock has a market capitalization of $20.52 billion, a P/E ratio of 26.51 and a beta of 0.93. The company has a 50 day moving average price of $216.98 and a 200 day moving average price of $238.63. STERIS plc has a fifty-two week low of $195.14 and a fifty-two week high of $269.44.

STERIS (NYSE:STE) last released its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.STERIS’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.74 earnings per share. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities research analysts forecast that STERIS plc will post 11.18 EPS for the current year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be issued a dividend of $0.63 per share. The ex-dividend date is Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. STERIS’s dividend payout ratio is 31.78%.

Wall Street Analysts Forecast Growth

STE has been the subject of a number of recent analyst reports. Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday. KeyCorp cut their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Finally, Piper Sandler restated an “overweight” rating and set a $270.00 price target on shares of STERIS in a report on Thursday, May 21st. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, STERIS presently has an average rating of “Moderate Buy” and a consensus target price of $278.00.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.